Neusoft Medical Systems Co Ltd, based in Shenyang, China, recently launched its CE-certified and FDA-approved NeuSight PET/CT system for global markets.
According to Neusoft Medical Systems, the NeuSight PET/CT system has the capability to create super-fine and low-dose images, which can provide accurate diagnostic information.
Neusoft Medical Systems had previously collaborated with Positron Corporation, a cardiac PET company based in the US that is now fully owned by Neusoft. The NeuSight PET/CT was developed by combining the technology know-how of Neusoft and Positron, with the R&D for the NeuSight scanner starting in 2012, passing factory verification in 2014, and passing CE certification and FDA approval in 2015.
Neusoft reports that the NeuSight PET/CT system is equipped with high-end electronics that offer high-quality diagnostic images with fast acquisition and post processing speeds. The NeuSight is designed to provide radiologists and nuclear medicine specialists with high throughput and a positive return on investment, and helps facilities make patient safety a top priority.
The company, which has been providing CT, MRI, PET/CT, x-ray, ultrasound, linear accelerator, and in vitro diagnostic products and services in China for 20 years, has established software development as its core competency. The company has subsidiaries in the US, United Arab Emirates, Peru, Brazil, Russia, and Vietnam.
For more information about the NeuSight and other PET/CT systems, visit the Neusoft website.
